Table 4.

Baseline Characteristics of Median Baseline Cardiac Composite Impairment Score (CCIS)

	Low CCIS* (n=37)	High CCIS* (n=36)	P-value
Age	58.4 ±11.4	53.7 ±11.7	0.080
Male	31 (83.78%)	31 (86.11%)	1.000
Race (white)	32(86.49%)	32(88.89%)	1.000
Diabetes	5(13.51%)	8(22.22%)	0.374
Hypertension	17(45.95%)	21(58.33%)	0.352
Hyperlipidemia	26(70.27%)	25(69.44%)	1.000
Angina	10(27.03%)	5(13.89%)	0.247
Smoking	19(51.35%)	23(63.89%)	0.346
Pre-infarction Angina	11(30.56%)	9(25.00%)	0.793
BMI†	27.8 ± 4.6	27.0 ±4.4	0.467
Peak CKMB‡	189.5 ±156.1	363.2 ±265.4	0.005
Peak Troponin T1	5.3 ± 4.8	11.4 ±6.5	0.011
Peak Troponin I1	71.4 ± 58.6	233.4 ± 215.6	0.025
Door to Balloon Time	4.0 ± 6.8)	9.4 ± 26.9	0.245
ACE§ inhibition	28(75.68%)	26(72.22%)	0.794
Anti-angina therapy	5(13.51%)	3(8.33%)	0.711
Anticoagulants	8(21.62%)	12(33.33%)	0.302
Non Aspirin Antiplatelet	29(78.38%)	34(94.44%)	0.085
Aspirin	36(97.30%)	34(94.44%)	0.615
Beta blockers	30(81.08%)	34(94.44%)	0.152
Calcium Channel Blockers	0(0.0%)	1(2.78%)	0.493
Cholesterol Lowering	35(94.59%)	35(97.22%)	1.000
Diuretic use	3(8.11%)	12(33.33%)	0.010
Insulin	2(5.41%)	2(5.56%)	1.000
Nitrates	12(32.43%)	14(38.89%)	0.630
Oral hypoglycemics	3(8.11%)	3(8.33%)	1.000

^*CCIS, Composite Cardiac Impairment Score; A low CCIS corresponds to less LV dysfunction at baseline (i.e., better LV function), while the converse is true for a high CCIS.

^†BMI, Body-mass index;

^‡CKMB, creatine kinase-MB;

^§ACE, Angiotensin-converting enzyme